» Articles » PMID: 24197801

Novel SMARCAL1 Bi-allelic Mutations Associated with a Chromosomal Breakage Phenotype in a Severe SIOD Patient

Overview
Journal J Clin Immunol
Publisher Springer
Date 2013 Nov 8
PMID 24197801
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Chromosomal instability syndromes include a group of rare diseases characterized by defective DNA-damage-response and increased risk of chromosomal breakage. Patients display defects in the recognition and/or repair of DNA damage, with a subsequent high rate of malignancies and abnormal gene rearrangements. Other clinical manifestations, such as immunodeficiency, neurodevelopmental delay and skeletal abnormalities, are present in some of these syndromes. We studied a patient with profound T-lymphocyte defect, neurodevelopmental delay, facial dysmorphism, nephrotic syndrome and spondyloepiphyseal bone dysplasia typical of SIOD.

Methods: Karyotype and chromosome fragility assays on patients' peripheral blood mononuclear cells showed an abnormal rate of spontaneous breaks. Cell cycle analysis of patient's fibroblasts following replication stress induced by hydroxyhurea revealed a delay in their release from S-phase to G2. When using higher concentrations of hydroxyhurea no patient fibroblast colonies could survive, compared with control fibroblasts. Whole-exome sequencing revealed novel compound heterozygote mutations in SMARCAL1 gene, resulting in putative frame shifts of encoded SMARCAL1 from each allele and no detected protein in patient's cells. The patient's youngest brother was found to have similar manifestations of SIOD but of less severity, including short stature, facial dysmorphism and typical osseous dysplasia, but no clinical findings suggestive of immunodeficiency and no chromosomal fragility. Similar to his sister, the brother carries both bi-allelic mutations in SMARCAL1 gene.

Conclusions: We present here the first evidence of intrinsic chromosomal instability in a severe SMARCAL1-deficient patient with a clinical picture of SIOD. Our results are consistent with the recently outlined role of SMARCAL1 protein in DNA damage response.

Citing Articles

Genetic and Clinical Features of Schimke Immuno-Osseous Dysplasia: Single-Centre Retrospective Study of 21 Unrelated Paediatric Patients over a Period of 20 Years.

Milovanova A, Ananin P, Vashurina T, Zrobok O, Dmitrienko S, Ryaposova A Int J Mol Sci. 2025; 26(4).

PMID: 40004207 PMC: 11855709. DOI: 10.3390/ijms26041744.


What happens to the osteoporotic bone mesenchymal stem cells? Evidence from RNA sequencing.

Li M, Cong R, Wang H, Ma C, Lv Y, Zheng Y Int J Med Sci. 2024; 21(1):95-106.

PMID: 38164361 PMC: 10750345. DOI: 10.7150/ijms.88146.


Pathological consequences of DNA damage in the kidney.

Garaycoechea J, Quinlan C, Luijsterburg M Nat Rev Nephrol. 2023; 19(4):229-243.

PMID: 36702905 DOI: 10.1038/s41581-022-00671-z.


Whole Exome Sequencing Identified a Novel Biallelic Mutation in the Extremely Rare Disease SIOD.

Jin J, Wu K, Liu Z, Chen X, Jiang S, Wang Z Front Genet. 2019; 10:565.

PMID: 31275356 PMC: 6591458. DOI: 10.3389/fgene.2019.00565.


The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.

Diplas B, He X, Brosnan-Cashman J, Liu H, Chen L, Wang Z Nat Commun. 2018; 9(1):2087.

PMID: 29802247 PMC: 5970234. DOI: 10.1038/s41467-018-04448-6.


References
1.
Esmer C, Sanchez S, Ramos S, Molina B, Frias S, Carnevale A . DEB test for Fanconi anemia detection in patients with atypical phenotypes. Am J Med Genet A. 2003; 124A(1):35-9. DOI: 10.1002/ajmg.a.20327. View

2.
Frommolt P, Abdallah A, Altmuller J, Motameny S, Thiele H, Becker C . Assessing the enrichment performance in targeted resequencing experiments. Hum Mutat. 2012; 33(4):635-41. DOI: 10.1002/humu.22036. View

3.
Betous R, Mason A, Rambo R, Bansbach C, Badu-Nkansah A, Sirbu B . SMARCAL1 catalyzes fork regression and Holliday junction migration to maintain genome stability during DNA replication. Genes Dev. 2012; 26(2):151-62. PMC: 3273839. DOI: 10.1101/gad.178459.111. View

4.
Postow L, Woo E, Chait B, Funabiki H . Identification of SMARCAL1 as a component of the DNA damage response. J Biol Chem. 2009; 284(51):35951-61. PMC: 2791023. DOI: 10.1074/jbc.M109.048330. View

5.
Lou S, Lamfers P, McGuire N, Boerkoel C . Longevity in Schimke immuno-osseous dysplasia. J Med Genet. 2002; 39(12):922-5. PMC: 1757210. DOI: 10.1136/jmg.39.12.922. View